Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dolutegravir und Rilpivirin, ATC J05AR21
Opportunity Score
Confidence: 60%
Complexity: low
719 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
This is an open-house model (not a traditional tender) by AOK Bayern for non-exclusive discount agreements on pharmaceuticals containing Dolutegravir and Rilpivirin (ATC J05AR21). All interested pharmaceutical companies that meet eligibility can enter identical, non-negotiable contracts. Contracts can be concluded anytime until 2028-06-03, with earliest start 2026-08-01, ending 2028-07-31. The model is not subject to procurement law.
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- The company must be a pharmaceutical company (pharmazeutischer Unternehmer).
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission of the signed contract including the annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Identifier
DE811695320
Lots (1)
Non-exclusive discount agreements for pharmaceuticals with active substances Dolutegravir and Rilpivirin. Contracts are identical for all participants. Place of performance: DE212 (Upper Bavaria).
Procurement Details
Publication
14 Jun 2026
Deadline
03 Jun 2028, 10:00
Procedure
open
Contract
supplies
Language
DEU
Publication #
407096-2026
Classification
Performance: Germany
Documents (2)
Opportunity Score
Confidence: 60%
Complexity: low
719 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation